Hisako Okuhira

Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab

Yasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka et al. · Journal of Dermatological Science · 2017 · 101 citations

Medicine, Immunology, Oncology +16

Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study

Taku Fujimura, Yota Sato, Kayo Tanita et al. · Oncotarget · 2018 · 90 citations · Full text

Medicine, Dermatology, Oncology +17

Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients

Yasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka et al. · Journal of Dermatological Science · 2017 · 68 citations

Life Sciences, Immunology, Oncology +12

Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma

Taku Fujimura, Yota Sato, Kayo Tanita et al. · Frontiers in Oncology · 2018 · 32 citations · Full text

Medicine, Immunology, Oncology +17

Clinical and histological evaluation of a single high energy microwave treatment for primary axillary hyperhidrosis in Asians: A prospective, randomized, controlled, split‐area comparative trial

Chikako Kaminaka, Naoya Mikita, Yutaka Inaba et al. · Lasers in Surgery and Medicine · 2019 · 23 citations

Medicine, Dermatology, Dermatopathology +13